Geisler Ferd E A, de Lange Simon, Royston David, Demeyere Roland, Duthie David J R, Lehot Jean-Jacques, Adt Monika, Dupeyron Jean-Pierre, Mansfield Martin, Kirkham Andrew J T
Department of Anaesthesiology, Ignatius Ziekenhuis Breda, Breda, The Netherlands.
J Cardiothorac Vasc Anesth. 2003 Feb;17(1):60-8. doi: 10.1053/jcan.2003.11.
To compare the efficacy and safety of 3 doses of remifentanil as part of a total intravenous anesthesia technique with low-dose propofol in patients undergoing coronary artery bypass graft (CABG) surgery.
Multicenter, multinational, double-blind, randomized, dose comparison study.
Nine hospitals in 5 countries.
One hundred forty-one patients undergoing first-time elective CABG surgery.
Patients were premedicated with a short-acting oral benzodiazepine up to 2 h before surgery and randomized to receive continuous infusions of remifentanil 1.0 microg/kg/min (n = 45), 1.5 microg/kg/min (n = 44), or 2.0 microg/kg/min (n = 43), in combination with propofol 3 mg/kg/h. Nine patients received remifentanil 1.0 microg/kg/min on an open-label basis. Three different induction sequences (IS) were used. In IS 1 (n = 31), induction was started with remifentanil infusion followed 5 minutes later by propofol 0.5 mg/kg bolus and infusion at 3 mg/kg/h. Further bolus doses of propofol (10 mg) were given if loss of consciousness (LOC) was not attained after 5 minutes; pancuronium, 0.04 to 0.1 mg/kg, was administered at LOC. In IS 2 (n = 68), a priming dose of pancuronium, 0.015 mg/kg, was administered just before starting remifentanil. In IS 3 (n = 42), bolus doses of propofol, 10 mg every 10 seconds, were given until LOC, followed by pancuronium, 0.04 to 0.1 mg/kg, and the remifentanil and propofol infusions were started.
There were no significant differences among the remifentanil dose groups with regard to the primary outcome measure, responses to sternotomy/sternal spread/maximal sternal spread. Responses to these stimuli were recorded in 11%, 11%, and 14% of patients in the remifentanil 1.0, 1.5, and 2.0 microg/kg/min dose groups, respectively. Similarly, there were no significant differences in the responses to other surgical stimuli. There was a high incidence of muscle rigidity when remifentanil was used to induce anesthesia.
All 3 remifentanil dose regimens provided profound suppression of responses to surgical stimuli in the majority of patients. There was no apparent advantage in starting the remifentanil infusion rate above 1.0 microg/kg/min. Remifentanil is not suitable for use as a sole induction agent.
比较3种剂量瑞芬太尼作为全凭静脉麻醉技术一部分与低剂量丙泊酚联合用于冠状动脉旁路移植术(CABG)患者的有效性和安全性。
多中心、跨国、双盲、随机、剂量比较研究。
5个国家的9家医院。
141例首次接受择期CABG手术的患者。
患者在手术前2小时内口服短效苯二氮䓬类药物进行术前用药,然后随机接受瑞芬太尼持续输注,剂量分别为1.0微克/千克/分钟(n = 45)、1.5微克/千克/分钟(n = 44)或2.0微克/千克/分钟(n = 43),同时联合丙泊酚3毫克/千克/小时。9例患者接受开放标签的瑞芬太尼1.0微克/千克/分钟输注。使用了3种不同的诱导顺序(IS)。在IS 1(n = 31)中,先开始输注瑞芬太尼,5分钟后静脉推注丙泊酚0.5毫克/千克并以3毫克/千克/小时的速度输注。如果5分钟后未达到意识消失(LOC),则给予更多丙泊酚推注剂量(10毫克);在LOC时给予泮库溴铵,0.04至0.1毫克/千克。在IS 2(n = 68)中,在开始输注瑞芬太尼前即刻给予泮库溴铵首剂,0.015毫克/千克。在IS 3(n = 42)中,每隔10秒静脉推注丙泊酚10毫克,直至LOC,随后给予泮库溴铵,0.04至0.1毫克/千克,然后开始输注瑞芬太尼和丙泊酚。
在主要结局指标即对胸骨切开术/胸骨撑开/最大胸骨撑开的反应方面,瑞芬太尼剂量组之间无显著差异。瑞芬太尼1.0、1.5和2.0微克/千克/分钟剂量组中分别有11%、11%和14%的患者记录到对这些刺激的反应。同样,对其他手术刺激的反应也无显著差异。使用瑞芬太尼诱导麻醉时肌肉强直的发生率较高。
所有3种瑞芬太尼剂量方案在大多数患者中均能深度抑制对手术刺激的反应。瑞芬太尼输注速率起始高于1.0微克/千克/分钟并无明显优势。瑞芬太尼不适合单独用作诱导药物。